Abstract:ABSTRACT The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.

Expression of the Receptor-Binding Region of SARS-CoV Spike Protein in Baculovirus Vector and Identifying Its Antigenicity

Expression of Soluble H1N1 Haemegglutinin in Two Distinct Insect Baculovirus Expression Systems

Baculovirus Surface Display Of Sars Coronavirus (Sars-Cov) Spike Protein And Immunogenicity Of The Displayed Protein In Mice Models

Expression Spike Protein and Membrane Protein of SARS-coronavirus in the Insect Baculovirus

Cloning, Expression, Purification of a Fusion Protein of SARS-CoV Nucleocapsid and Spike Protein Fragments and Its Immunological Characteristics

Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity

[Expression and Purification of Recombinant SARS Coronavirus Spike Protein].

Expression of E2 Protein of Classical Swine Fever Virus Shimen Strain Using Baculovrius Expression System

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Receptor-binding Domain of SARS-Cov Spike Protein: Soluble Expression in E. Coli, Purification and Functional Characterization.

[Expression and Purification of Recombinant N-terminal Protein of SARS S1 Subunit Expressed in E. Coli].

Expression, purification and sublocalization of SARS-CoV nucleocapsid protein in insect cells.

[A Preliminary Study of the Structure Prediction and Expression of SARS-CoV Spike Protein].

Utilization of Recombinant Baculovirus Expression System to Produce the RBD Domain of SARS-CoV-2 Spike Protein

A Strategy for Searching Antigenic Regions in the SARS-CoV Spike Protein

Expression of SARS Coronavirus Spike Protein in E. Coli and Silkworm Bombyx Mori

Construction of a Eukaryotic Expression Plasmid Encoding Partial S Gene Fragments of the SARS-CoV and Its Potential Utility As a DNA Vaccine

Display of Receptor-Binding Domain of SARS-CoV Spike Protein on the Yeast Cell Surface

Expression and Identification of SARS-CoV Nucleocapsid Protein

Expression of Receptor-binding Domain of SARS-CoV Spike Protein and Isolation of Highly Potent Neutralizing Antibody

Harnessing coronavirus spike proteins' binding affinity to ACE2 receptor through a novel baculovirus surface display system